FEDERAL LOBBYING RECORDS
LOBBYING FILINGS AND MARKET CONTEXT
Indexed federal lobbying filings mapped to clients, registrants, and public-company tickers. Transaction dates are compared with filing periods to identify date-proximity review flags. Proximity does not establish coordination, influence, or wrongdoing.
Filings tracked
20,641
thru 2026-07-15
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,260
paying companies
Tickers targeted
1,219
public companies
Clients by reported amount
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 48 | $46.9M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 13 | $45.0M |
| 4 | VISA INC.V | 46 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 37 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 76 | $29.1M |
| 7 |  FEDEX CORPORATIONFDXW | 71 | $27.9M |
| 8 |  ELI LILLY AND COMPANYLLY | 60 | $27.4M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 147 | $25.3M |
| 10 |  COMCAST CORPORATIONCMCSV | 183 | $24.9M |
| 11 |  AMGEN INCAMGN | 19 | $24.9M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 54 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 83 | $22.8M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 131 | $21.3M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 41 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 32 | $19.8M |
| 20 |  MICROSOFT CORPORATIONMSFT | 107 | $18.9M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  BOEING COMPANYBA | 24 | $17.0M |
| 23 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 60 | $16.8M |
Mapped tickers by reported amount
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 134 | $50.3M |
| 2 | PFE Pfizer Inc. | 89 | $48.7M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 47 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 82 | $35.4M |
| 6 | LMT Lockheed Martin Corporation | 92 | $29.5M |
| 7 | FDX FedEx Corporation | 83 | $28.4M |
| 8 | LLY Eli Lilly and Company | 88 | $28.4M |
| 9 | AMGN Amgen Inc. | 100 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 66 | $27.0M |
| 12 | GOOGL Alphabet Inc. Class A | 128 | $26.8M |
| 13 | MO | 172 | $26.4M |
| 14 | SO Southern Company | 110 | $26.2M |
| 15 | UNH UnitedHealth Group Inc. | 68 | $24.0M |
| 16 | VZ Verizon Communications Inc. | 119 | $23.8M |
| 17 | TMUS | 170 | $22.9M |
| 18 |  CHTR | 142 | $22.8M |
| 19 | GD General Dynamics Corporation | 131 | $22.6M |
| 20 |  TAT&T Inc. | 137 | $21.7M |
| 21 | ORCL Oracle Corporation | 135 | $20.8M |
| 22 | CMCSA Comcast Corporation | 142 | $20.5M |
| 23 | OXY Occidental Petroleum Corporation | 38 | $20.1M |
| 24 | CI The Cigna Group | 64 | $19.9M |
| 25 | MSFT Microsoft Corporation | 126 | $19.3M |
🆕 Filtered Filings · ARDELYX INC.
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-07-15 | ARDX | ARDELYX INC. | ARDELYX, INC. | $500K | Access to innovative medications for people with kidney failure; reimbursement; drug pricing; most favored nation drug pricing; Medicare kidney care access and payment issues. |
| 2026-07-05 | ARDX | ARDELYX INC. | LMH STRATEGIC SOLUTIONS | $30K | General health care coverage and reimbursement for prescription drugs. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues. |
| 2026-04-22 | ARDX | ARDELYX INC. | ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) | $90K | Issues related to coverage and reimbursement under Medicare Part D. |
| 2026-04-20 | ARDX | ARDELYX INC. | ARDELYX, INC. | $560K | Access to innovative kidney treatments, ESRD PPS, coverage of oral only medications for people with ESRD, innovation, Drug pricing, Medicare access to pharmaceuticals. |
| 2026-04-20 | ARDX | ARDELYX INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $40K | Issues related to Medicare ESRD benefit and chronic kidney disease management Issues related to medication affordability and access |
| 2026-04-19 | ARDX | ARDELYX INC. | CAPITOL COUNSEL LLC | $0 | |
| 2026-04-18 | ARDX | ARDELYX INC. | THORN RUN PARTNERS | $60K | Issues related to Medicare ESRD benefit and chronic kidney disease management. Most-Favored-Nation (MFN) issues. |
| 2026-04-17 | ARDX | ARDELYX INC. | LMH STRATEGIC SOLUTIONS | $30K | General health care coverage and reimbursement for prescription drugs. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues. |
| 2026-04-16 | ARDX | ARDELYX INC. | CAPITOL CITY GROUP, LTD. | $0 | |
| 2026-03-09 | ARDX | ARDELYX INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $40K | Issues related to Medicare ESRD benefit and chronic kidney disease management Issues related to medication affordability and access |
| 2026-01-20 | ARDX | ARDELYX INC. | ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC) | $90K | Issues related to coverage and reimbursement under Medicare Part D. |
| 2026-01-20 | ARDX | ARDELYX INC. | THORN RUN PARTNERS | $60K | Issues related to Medicare ESRD benefit and chronic kidney disease management. |
| 2026-01-20 | ARDX | ARDELYX INC. | CAPITOL CITY GROUP, LTD. | $50K | Assist client with matters re: kidney dialysis drugs and renal drugs; assist client with medicare/CMS issues; assist re: issues on ESRD related drugs and medicare ESRD prospective payment system. |
| 2026-01-20 | ARDX | ARDELYX INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $40K | Issues related to Medicare ESRD benefit and chronic kidney disease management Issues related to medication affordability and access |
| 2026-01-19 | ARDX | ARDELYX INC. | ARDELYX, INC. | $580K | Access to innovative kidney treatments, ESRD PPS, coverage of oral only medications for people with ESRD, innovation, Drug pricing, Medicare access to pharmaceuticals |
| 2026-01-19 | ARDX | ARDELYX INC. | CAPITOL COUNSEL LLC | $60K | Issues regarding ESRD-related drugs and the Medicare ESRD prospective payment system. Issues regarding ESRD-related drugs and the Medicare ESRD prospective payment system. |
| 2026-01-12 | ARDX | ARDELYX INC. | LMH STRATEGIC SOLUTIONS | $30K | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2025-10-20 | ARDX | ARDELYX INC. | THORN RUN PARTNERS | $60K | Issues related to Medicare ESRD benefit and chronic kidney disease management. |
| 2025-10-20 | ARDX | ARDELYX INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $40K | Issues related to Medicare ESRD benefit and chronic kidney disease management Issues related to medication affordability and access |
| 2025-10-20 | ARDX | ARDELYX INC. | LMH STRATEGIC SOLUTIONS | $30K | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2025-10-16 | ARDX | ARDELYX INC. | ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC) | $90K | Issues related to coverage and reimbursement under Medicare Part D. |
| 2025-10-16 | ARDX | ARDELYX INC. | CAPITOL COUNSEL LLC | $60K | Issues regarding ESRD-related drugs and the Medicare ESRD prospective payment system. Issues regarding ESRD-related drugs and the Medicare ESRD prospective payment system. |
| 2025-10-16 | ARDX | ARDELYX INC. | CAPITOL CITY GROUP, LTD. | $50K | Assist client with matters re: kidney dialysis drugs and renal drugs; assist client with medicare/CMS issues; assist re: issues on ESRD related drugs and medicare ESRD prospective payment system. |
| 2025-10-08 | ARDX | ARDELYX INC. | ARDELYX, INC. | $650K | Access to innovative kidney treatments. H.R.5074 - Protecting Young Minds Online Act, S.4510 - Kidney PATIENT Act of 2024. Pharmaceutical pricing proposals, Medicare pharmaceutical payment and access issues. Coverage of oral only End-Stage Renal Disease drugs. |
| 2025-09-25 | ARDX | ARDELYX INC. | JEFFREY J. KIMBELL & ASSOCIATES, INC. | $40K | Issues related to Medicare ESRD benefit and chronic kidney disease management Issues related to medication affordability and access |
| 2025-09-16 | ARDX | ARDELYX INC. | ARDELYX, INC. | $620K | Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act |
| 2025-07-20 | ARDX | ARDELYX INC. | ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC) | $90K | Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act |
| 2025-07-18 | ARDX | ARDELYX INC. | ARDELYX, INC. | $540K | H.R.5074, S.4510, Kidney Patient Act, Kidney Health Equity. Access to Innovative Kidney Treatments. Medicaid rebate, most favored nation drug pricing. Increase Access to Innovation for People with Kidney Failure. Support Medicare Part D access to phosphorus-lowering medications. |
| 2025-07-18 | ARDX | ARDELYX INC. | CAPITOL COUNSEL LLC | $60K | Issues regarding ESRD-related drugs and the Medicare ESRD prospective payment system. Issues regarding ESRD-related drugs and the Medicare ESRD prospective payment system. |
| 2025-07-18 | ARDX | ARDELYX INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $40K | Issues related to Medicare ESRD benefit and chronic kidney disease management Issues related to medication affordability and access |
| 2025-07-15 | ARDX | ARDELYX INC. | THORN RUN PARTNERS | $60K | Issues related to Medicare ESRD benefit and chronic kidney disease management. |
| 2025-07-15 | ARDX | ARDELYX INC. | LMH STRATEGIC SOLUTIONS | $0 | Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues. |
| 2025-07-11 | ARDX | ARDELYX INC. | CAPITOL CITY GROUP, LTD. | $50K | Assist client with matters re: kidney dialysis drugs and renal drugs; assist client with medicare/CMS issues; assist re: issues on ESRD related drugs and medicare ESRD prospective payment system. |
| 2025-04-20 | ARDX | ARDELYX INC. | ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC) | $90K | Issues related to the incorporation of oral drugs indicated for the reduction, management, or control of the serum phosphate of an individual into the End-Stage Renal Disease (ESRD) Prospective Payment System. |
| 2025-04-19 | ARDX | ARDELYX INC. | CAPITOL COUNSEL LLC | $60K | Issues regarding ESRD-related drugs and the Medicare ESRD prospective payment system. Issues regarding ESRD-related drugs and the Medicare ESRD prospective payment system. |
| 2025-04-18 | ARDX | ARDELYX INC. | ARDELYX, INC. | $620K | Medicare, ESRD Bundle, H.R.5074, S.4510, Kidney Patient Act |
| 2025-04-18 | ARDX | ARDELYX INC. | JEFFREY J. KIMBELL AND ASSOCIATES | $40K | Issues related to Medicare ESRD benefit and chronic kidney disease management Issues related to medication affordability and access |
| 2025-04-17 | ARDX | ARDELYX INC. | CAPITOL CITY GROUP, LTD. | $50K | Assist client with matters re: kidney dialysis drugs and renal drugs; assist client with medicare/CMS issues; assist re: issues on ESRD related drugs and medicare ESRD prospective payment system. |
| 2025-04-16 | ARDX | ARDELYX INC. | THORN RUN PARTNERS | $60K | Issues related to Medicare ESRD benefit and chronic kidney disease management. |
| 2025-01-21 | ARDX | ARDELYX INC. | CAPITOL CITY GROUP, LTD. | $20K | Assist client with legislation re: Kidney Patient Act; monitor legislation re: same. HR 5074-Kidney PATIENT Act of 2023; S 4510 Kidney PATIENT Act of 2024; Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2024. HR 6790 New "Era of Preventing End-Stage Kidney Disease Act; HR 5027-S4469 Kidney Disease Improvement in Research and Treatment Act of 2024. |
| 2025-01-20 | ARDX | ARDELYX INC. | ROBERTI GLOBAL (FKA ROBERTI WHITE, LLC) | $80K | Issues related to reimbursement under Medicare Part D; H.R. 5074/S.4510, the Kidney PATIENT Act |
| 2025-01-19 | ARDX | ARDELYX INC. | THORN RUN PARTNERS | $60K | Issues related to Medicare ESRD benefit and chronic kidney disease management. H.R.5074/S.4510 - Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023. |